Risk Audit · Cached SEC Snapshot
CTOR Risk Audit — Dilution, Cash Runway, and SEC Filings
CITIUS ONCOLOGY, INC.
TL;DR
- MODERATE / CAUTION — No fatal flags, but the structure is not pristine. Read the evidence.
- Doomsday Clock: 2.8mo of cash before the company exhausts its operating runway.
- Dilution Risk: 30 / 100 — company is actively issuing new shares.
- Dilution Status: Potential Dilution — Share count changed by +29.9%. No active dilution drivers detected in latest filing.
Doomsday Clock
2.8mo
Company runs out of cash in 2.8 months
Dilution Risk
30 / 100
Company actively issuing new shares
C
Stockteller Grade
Altman Z: -2.30 (Z)
Gravity Playbook · Mathematical Stress Test
AUTH
Dilution Authorization
The company has an active S-3 shelf registration. It is authorized to dilute up to 29.95% annually. Current mechanics indicate no active dilution.
BURN
Cash Runway
Current mechanics indicate cash runway is mathematically depleted in approximately 2.82 months.
COMPLIANCE
Nasdaq Compliance
Nasdaq requires a $1.00 minimum bid. Historical precedent for companies with this profile involves structural actions such as reverse splits to maintain listing compliance.
Mechanical analysis only. Not financial advice. Statements describe mathematical conditions and historical precedent, not predictions or recommendations for this security.
Educational analysis only. Not financial advice. The Risk Audit is a quantitative framework derived from publicly available SEC filings and may contain inaccuracies. AI systems are fallible. Always verify against the source filings on
SEC EDGAR
and consult a licensed advisor before making investment decisions.